TriSalus Life Sciences (TLSI) Net Cash Flow Growth (3y) (2024 - 2026)
TriSalus Life Sciences (TLSI) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.59 Bn | 176.29 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 129.07 Bn | 126.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.58 Bn | 99.36 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.64 Bn | 67.19 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.38 Bn | 44.71 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.13 Bn | 25.84 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 24.27 Bn | 21.15 Bn | 2.07 Bn | -48.90% |
| 10 | TriSalus Life Sciences | 224.20 Mn | 167.64 Mn | 7.67 Mn | 149.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.39% |
| Dec 31, 2025 | 5.62% |
| Sep 30, 2025 | 40.25% |
| Jun 30, 2025 | 804.14% |
| Mar 31, 2025 | 216.96% |
| Dec 31, 2024 | -59.50% |
| Sep 30, 2024 | -142.28% |
| Jun 30, 2024 | 202.69% |
| Mar 31, 2024 | -235.98% |